These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12895191)

  • 21. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Olanzapine (Zyprexa)].
    Sahebjam M; Serra E
    Presse Med; 2000 Dec; 29(38):2106-8. PubMed ID: 11147054
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.
    Esel E; Basturk M; Saffet Gonul A; Kula M; Tayfun Turan M; Yabanoglu I; Sofuoglu S
    Psychoneuroendocrinology; 2001 Aug; 26(6):641-7. PubMed ID: 11403983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mnestic impairment under olanzapine overdosage in an elderly patient].
    Grieshaber S; Jatzko A; Adler G
    Psychiatr Prax; 2002 Nov; 29(8):441-4. PubMed ID: 12436366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose olanzapine therapy in schizophrenia.
    Alao AO; Armenta WA; Yolles JC
    Ann Pharmacother; 1999 Nov; 33(11):1228. PubMed ID: 10573326
    [No Abstract]   [Full Text] [Related]  

  • 27. Olanzapine excretion in human breast milk: estimation of infant exposure.
    Croke S; Buist A; Hackett LP; Ilett KF; Norman TR; Burrows GD
    Int J Neuropsychopharmacol; 2002 Sep; 5(3):243-7. PubMed ID: 12366877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.
    Goff DC; Hennen J; Lyoo IK; Tsai G; Wald LL; Evins AE; Yurgelun-Todd DA; Renshaw PF
    Biol Psychiatry; 2002 Mar; 51(6):493-7. PubMed ID: 11922885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine transfer by human placenta.
    Schenker S; Yang Y; Mattiuz E; Tatum D; Lee M
    Clin Exp Pharmacol Physiol; 1999 Sep; 26(9):691-7. PubMed ID: 10499158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
    Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K
    Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine.
    Boulton DW; Markowitz JS; DeVane CL
    J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(2):319-23. PubMed ID: 11499485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants.
    Gardiner SJ; Kristensen JH; Begg EJ; Hackett LP; Wilson DA; Ilett KF; Kohan R; Rampono J
    Am J Psychiatry; 2003 Aug; 160(8):1428-31. PubMed ID: 12900304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
    Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
    J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions.
    Du P; Li P; Liu H; Zhao R; Zhao Z; Yu W; Zhou X; Liu L
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):621-628. PubMed ID: 31595704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
    Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF
    Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder.
    Hough DW
    J Clin Psychiatry; 2001 Apr; 62(4):296-7. PubMed ID: 11379847
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.
    Davis MP; Khawam E; Pozuelo L; Lagman R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):365-76. PubMed ID: 12647979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine in acute bipolar mania.
    Jagadheesan K
    Arch Gen Psychiatry; 2002 Feb; 59(2):188. PubMed ID: 11825144
    [No Abstract]   [Full Text] [Related]  

  • 39. Riluzole and olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Diez J; Költringer P
    Eur J Neurol; 2002 Mar; 9(2):183-4. PubMed ID: 11882065
    [No Abstract]   [Full Text] [Related]  

  • 40. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
    Nyberg S; Farde L; Halldin C
    Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.